Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Dec;51(12):1573-1578.
doi: 10.1038/bmt.2016.198. Epub 2016 Aug 1.

Marrow grafts from HLA-identical siblings for severe aplastic anemia: does limiting the number of transplanted marrow cells reduce the risk of chronic GvHD?

S Gallo  1 , A E Woolfrey  1   2 , L M Burroughs  1   2 , B E Storer  1   3 , M E D Flowers  1   4 , P Hari  5 , M A Pulsipher  6 , S Heimfeld  1 , H-P Kiem  1   4 , B M Sandmaier  1   4 , R Storb  1   4
Affiliations

Marrow grafts from HLA-identical siblings for severe aplastic anemia: does limiting the number of transplanted marrow cells reduce the risk of chronic GvHD?

S Gallo et al. Bone Marrow Transplant. 2016 Dec.

Abstract

A total of 21 patients with severe aplastic anemia (SAA) underwent marrow transplantation from HLA-identical siblings following a standard conditioning regimen with cyclophosphamide (50 mg/kg/day × 4 days) and horse antithymocyte globulin (30 mg/kg/day × 3 days). Post-grafting immunosuppression consisted of a short course of methotrexate (MTX) combined with cyclosporine (CSP). The transplant protocol tested the hypothesis that the incidence of chronic GvHD could be reduced by limiting the marrow grafts to ⩽2.5 × 108 nucleated marrow cells/kg. None of the patients rejected the graft, all had sustained engraftment and all are surviving at a median of 4 (range 1-8) years after transplantation. Chronic GvHD developed in 16% of patients given ⩽2.5 × 108 nucleated marrow cells/kg. Post-grafting immunosuppression has been discontinued in 20 of the 21 patients. In conclusion, limiting the number of transplanted marrow cells may have resulted in minimal improvement in the incidence and severity of chronic GvHD.

PubMed Disclaimer

Figures

Fig 1
Fig 1
(a) Cumulative incidence of chronic GvHD. (b) Probability of survival.
See this image and copyright information in PMC

References

    1. Storb R, Floersheim GL, Weiden PL, Graham TC, Kolb H-J, Lerner KG, et al. Effect of prior blood transfusions on marrow grafts: Abrogation of sensitization by procarbazine and antithymocyte serum. J Immunol. 1974;112:1508–1516. - PubMed
    1. Weiden PL, Storb R, Slichter S, Warren RP, Sale GE. Effect of six weekly transfusions on canine marrow grafts: Tests for sensitization and abrogation of sensitization by procarbazine and antithymocyte serum. J Immunol. 1976;117:143–150. - PubMed
    1. Storb R, Thomas ED, Buckner CD, Clift RA, Johnson FL, Fefer A, et al. Allogeneic marrow grafting for treatment of aplastic anemia. Blood. 1974;43:157–180. - PubMed
    1. van Bekkum DW, Bach F, Bergan JJ, Bortin MM, Buckley RH, Good RA, et al. Bone marrow transplantation from histocompatible, allogeneic donors for aplastic anemia. A report from the ACS/NIH bone marrow transplant registry. JAMA. 1976;236:1131–1135. - PubMed
    1. Bortin MM, Rimm AA. Treatment of 144 patients with severe aplastic anemia using immunosuppression and allogeneic marrow transplantation. A report from the International Bone Marrow Registry. Transplant Proc. 1981;13:227–233. - PubMed